Prostate specifi c antigen as a tumor marker in prostate cancer: Biochemical and clinical aspects

Advances in Experimental Medicine and Biology

Volumn 867, Issue , 2015, Pages 93-114

  Salman, J W ^a   Schoots, I G ^a   Carlsson, S V ^a   Jenster, G ^a   Roobol, M J ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Diagnostic tool s in prostate cancer; Free PSA; Molecular forms of PSA; mpMRI; PCA3; Percent free PSA; ProPSA; Prostate; Prostate cancer; Prostate health index; PSA assays; PSA density; PSA velocity; PSA doubling time; PSA biology; PSA cut off value; PSA derived parameters; PSA kinetics; PSA physiology; TMPRSS2: ERG gene fusion

Indexed keywords

PROSTATE CANCER ANTIGEN 3; PROSTATE SPECIFIC ANTIGEN; TUMOR MARKER; UNCLASSIFIED DRUG;

BIOCHEMICAL RECURRENCE; CANCER DIAGNOSIS; CANCER SCREENING; CANCER STAGING; DIAGNOSTIC ACCURACY; DIGITAL RECTAL EXAMINATION; GENE FUSION; GLEASON SCORE; HUMAN; IMAGE GUIDED BIOPSY; NOMOGRAM; NUCLEAR MAGNETIC RESONANCE IMAGING; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROSTATE VOLUME; PROSTATECTOMY; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; TMPRSS2 ERG GENE FUSION; TRANSRECTAL ULTRASONOGRAPHY; BLOOD; EARLY DIAGNOSIS; MALE; PROSTATIC NEOPLASMS;

EARLY DETECTION OF CANCER; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS;

EID: 84946902588     PISSN: 00652598     EISSN: 22148019     Source Type: Book Series    
DOI: 10.1007/978-94-017-7215-0_7     Document Type: Chapter

References (132)

1. Villeirs GM, LV K, De Neve WJ, De Meerleer GO (2005) Magnetic resonance imaging anatomy of the prostate and periprostatic area: a guide for radiotherapists. Radiother Oncol 76(1):99–106
2. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM (2010) Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127(12):2893–2917
3. Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JW, Comber H et al (2013) Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer 49(6):1374–1403
4. Siegel R, Naishadham D, Jemal A (2013) Cancer statistics, 2013. CA Cancer J Clin 63(1):11–30
5. Center MM, Jemal A, Lortet-Tieulent J, Ward E, Ferlay J, Brawley O et al (2012) International variation in prostate cancer incidence and mortality rates. Eur Urol 61(6):1079–1092
6. Gosselaar C, Kranse R, Roobol MJ, Roemeling S, Schroder FH (2008) The interobserver variability of digital rectal examination in a large randomized trial for the screening of prostate cancer. Prostate 68(9):985–993
7. Hodge KK, McNeal JE, Terris MK, Stamey TA (1989) Random systematic versus directed ultrasound guided transrectal core biopsies of the prostate. J Urol 142(1):71–74, discussion 4–5
8. Gleason DF (1966) Classifi cation of prostatic carcinomas. Cancer Chemother Rep 50(3):125–128
9. Mellinger GT, Gleason D, Bailar J 3rd (1967) The histology and prognosis of prostatic cancer. J Urol 97(2):331–337
10. Epstein JI, Allsbrook WC Jr, Amin MB, Egevad LL, Committee IG (2005) The 2005 International Society of Urological Pathology (ISUP) consensus conference on gleason grading of prostatic carcinoma. Am J Surg Pathol 29(9):1228–1242
11. Yousef GM, Luo LY, Diamandis EP (1999) Identifi cation of novel human kallikrein-like genes on chromosome 19q13.3-q13.4. Anticancer Res 19(4B):2843–2852
12. Hara M, Koyanagi Y, Inoue T, Fukuyama T (1971) Some physico-chemical characteristics of “– seminoprotein”, an antigenic component specifi c for human seminal plasma. Forensic immunological study of body fl uids and secretion. VII. Nihon Hoigaku Zasshi 25(4):322–324
13. Wang MC, Valenzuela LA, Murphy GP, Chu TM (1979) Purifi cation of a human prostate specifi c antigen. Invest Urol 17(2):159–163
14. Li TS, Beling CG (1973) Isolation and characterization of two specifi c antigens of human seminal plasma. Fertil Steril 24(2):134–144
15. Papsidero LD, Wang MC, Valenzuela LA, Murphy GP, Chu TM (1980) A prostate antigen in sera of prostatic cancer patients. Cancer Res 40(7):2428–2432
16. Yousef GM, Diamandis EP (2001) The new human tissue kallikrein gene family: structure, function, and association to disease. Endocr Rev 22(2):184–204
17. Balk SP, Ko YJ, Bubley GJ (2003) Biology of prostate- specifi c antigen. J Clin Oncol 21(2):383–391
18. Lilja H (1985) A kallikrein-like serine protease in prostatic fl uid cleaves the predominant seminal vesicle protein. J Clin Invest 76(5):1899–1903
19. Lovgren J, Valtonen-Andre C, Marsal K, Lilja H, Lundwall A (1999) Measurement of prostatespecifi c antigen and human glandular kallikrein 2 in different body fl uids. J Androl 20(3):348–355
20. Stephan C, Jung K, Lein M, Diamandis EP (2007) PSA and other tissue kallikreins for prostate cancer detection. Eur J Cancer 43(13):1918–1926
21. Stamey TA, Yang N, Hay AR, McNeal JE, Freiha FS, Redwine E (1987) Prostate-specifi c antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med 317(15):909–916
22. Oesterling JE, Chan DW, Epstein JI, Kimball AW Jr, Bruzek DJ, Rock RC et al (1988) Prostate specifi c antigen in the preoperative and postoperative evaluation of localized prostatic cancer treated with radical prostatectomy. J Urol 139(4):766–772
23. Kumar A, Mikolajczyk SD, Goel AS, Millar LS, Saedi MS (1997) Expression of pro form of prostatespecifi c antigen by mammalian cells and its conversion to mature, active form by human kallikrein 2. Cancer Res 57(15):3111–3114
24. Mikolajczyk SD, Millar LS, Wang TJ, Rittenhouse HG, Wolfert RL, Marks LS et al (2000) “BPSA,” a specifi c molecular form of free prostate-specifi c antigen, is found predominantly in the transition zone of patients with nodular benign prostatic hyperplasia. Urology 55(1):41–45
25. Mikolajczyk SD, Millar LS, Wang TJ, Rittenhouse HG, Marks LS, Song W et al (2000) A precursor form of prostate-specifi c antigen is more highly elevated in prostate cancer compared with benign transition zone prostate tissue. Cancer Res 60(3):756–759
26. Mikolajczyk SD, Grauer LS, Millar LS, Hill TM, Kumar A, Rittenhouse HG et al (1997) A precursor form of PSA (pPSA) is a component of the free PSA in prostate cancer serum. Urology 50(5):710–714
27. Link RE, Shariat SF, Nguyen CV, Farr A, Weinberg AD, Morton RA et al (2004) Variation in prostate specifi c antigen results from 2 different assay platforms: clinical impact on 2304 patients undergoing prostate cancer screening. J Urol 171(6 Pt 1):2234–2238
28. Loeb S, Catalona WJ (2008) What to do with an abnormal PSA test. Oncologist 13(3):299–305
29. Blijenberg BG, Yurdakul G, Van Zelst BD, Bangma CH, Wildhagen MF, Schroder FH (2001) Discordant performance of assays for free and total prostate- specifi c antigen in relation to the early detection of prostate cancer. BJU Int 88(6):545–550
30. Rafferty B, Rigsby P, Rose M, Stamey T, Gaines DR (2000) Reference reagents for prostate-specifi c antigen (PSA): establishment of the fi rst international standards for free PSA and PSA (90:10). Clin Chem 46(9):1310–1317
31. Bangma CH, van Schaik RH, Blijenberg BG, Roobol MJ, Lilja H, Stenman UH (2010) On the use of prostate- specifi c antigen for screening of prostate cancer in European randomised study for screening of prostate cancer. Eur J Cancer 46(17):3109–3119
32. Thompson IM, Pauler DK, Goodman PJ, Tangen CM, Lucia MS, Parnes HL et al (2004) Prevalence of prostate cancer among men with a prostate-specifi c antigen level < or =4.0 ng per milliliter. N Engl J Med 350(22):2239–2246
33. Oesterling JE (1991) Prostate specifi c antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J Urol 145(5):907–923
34. Nadler RB, Humphrey PA, Smith DS, Catalona WJ, Ratliff TL (1995) Effect of infl ammation and benign prostatic hyperplasia on elevated serum prostate specifi c antigen levels. J Urol 154(2 Pt 1):407–413
35. Thompson IM, Ankerst DP, Chi C, Lucia MS, Goodman PJ, Crowley JJ et al (2005) Operating characteristics of prostate-specifi c antigen in men with an initial PSA level of 3.0 ng/ml or lower. JAMA 294(1):66–70
36. Schroder FH, Carter HB, Wolters T, van den Bergh RC, Gosselaar C, Bangma CH et al (2008) Early detection of prostate cancer in 2007. Part 1: PSA and PSA kinetics. Eur Urol 53(3):468–477
37. Draisma G, Boer R, Otto SJ, van der Cruijsen IW, Damhuis RA, Schroder FH et al (2003) Lead times and overdetection due to prostate-specifi c antigen screening: estimates from the European randomized study of screening for prostate cancer. J Natl Cancer Inst 95(12):868–878
38. Stenman UH, Leinonen J, Alfthan H, Rannikko S, Tuhkanen K, Alfthan O (1991) A complex between prostate-specifi c antigen and alpha 1- antichymotrypsin is the major form of prostatespecifi c antigen in serum of patients with prostatic cancer: assay of the complex improves clinical sensitivity for cancer. Cancer Res 51(1):222–226
39. Lilja H, Christensson A, Dahlen U, Matikainen MT, Nilsson O, Pettersson K et al (1991) Prostate-specifi c antigen in serum occurs predominantly in complex with alpha 1-antichymotrypsin. Clin Chem 37(9):1618–1625
40. Catalona WJ, Partin AW, Slawin KM, Brawer MK, Flanigan RC, Patel A et al (1998) Use of the percentage of free prostate-specifi c antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. JAMA 279(19):1542–1547
41. Roddam AW, Duffy MJ, Hamdy FC, Ward AM, Patnick J, Price CP et al (2005) Use of prostatespecifi c antigen (PSA) isoforms for the detection of prostate cancer in men with a PSA level of 2–10 ng/ml: systematic review and meta-analysis. Eur Urol 48(3):386–399, discussion 98–9
42. Lee R, Localio AR, Armstrong K, Malkowicz SB, Schwartz JS, Free PSASG (2006) A meta-analysis of the performance characteristics of the free prostate- specifi c antigen test. Urology 67(4):762–768
43. Catalona WJ, Southwick PC, Slawin KM, Partin AW, Brawer MK, Flanigan RC et al (2000) Comparison of percent free PSA, PSA density, and age-specifi c PSA cutoffs for prostate cancer detection and staging. Urology 56(2):255–260
44. Finne P, Auvinen A, Maattanen L, Tammela TL, Ruutu M, Juusela H et al (2008) Diagnostic value of free prostate-specifi c antigen among men with a prostate-specifi c antigen level of <3.0 microg per liter. Eur Urol 54(2):362–370
45. Catalona WJ, Bartsch G, Rittenhouse HG, Evans CL, Linton HJ, Horninger W et al (2004) Serum proprostate specifi c antigen preferentially detects aggressive prostate cancers in men with 2 to 4 ng/ml prostate specifi c antigen. J Urol 171(6 Pt 1):2239–2244
46. Mikolajczyk SD, Catalona WJ, Evans CL, Linton HJ, Millar LS, Marker KM et al (2004) Proenzyme forms of prostate-specifi c antigen in serum improve the detection of prostate cancer. Clin Chem 50(6):1017–1025
47. de Vries SH, Raaijmakers R, Blijenberg BG, Mikolajczyk SD, Rittenhouse HG, Schroder FH (2005) Additional use of [−2] precursor prostatespecifi c antigen and “benign” PSA at diagnosis in screen-detected prostate cancer. Urology 65(5): 926–930
48. Bangma CH, Wildhagen MF, Yurdakul G, Schroder FH, Blijenberg BG (2004) The value of (−7, −5)proprostate- specifi c antigen and human kallikrein-2 as serum markers for grading prostate cancer. BJU Int 93(6):720–724
49. Hori S, Blanchet JS, McLoughlin J (2013) From prostate-specifi c antigen (PSA) to precursor PSA (proPSA) isoforms: a review of the emerging role of proPSAs in the detection and management of early prostate cancer. BJU Int 112(6):717–728
50. Lein M, Semjonow A, Graefen M, Kwiatkowski M, Abramjuk C, Stephan C et al (2005) A multicenter clinical trial on the use of (−5, −7) pro prostate specifi c antigen. J Urol 174(6):2150–2153
51. Miyakubo M, Ito K, Yamamoto T, Takechi H, Ohi M, Suzuki K (2009) Proprostate-specifi c antigen: its usefulness in the era of multiple-core prostate biopsy. Int J Urol 16(6):561–565
52. Sokoll LJ, Sanda MG, Feng Z, Kagan J, Mizrahi IA, Broyles DL et al (2010) A prospective, multicenter, National Cancer Institute Early Detection Research Network study of [−2]proPSA: improving prostate cancer detection and correlating with cancer aggressiveness. Cancer Epidemiol Biomarkers Prev 19(5):1193–1200
53. Rhodes T, Jacobson DJ, McGree ME, St Sauver JL, Girman CJ, Lieber MM et al (2012) Longitudinal changes of benign prostate-specifi c antigen and [−2] proprostate-specifi c antigen in seven years in a community- based sample of men. Urology 79(3):655–661
54. Jansen FH, van Schaik RH, Kurstjens J, Horninger W, Klocker H, Bektic J et al (2010) Prostate-specifi c antigen (PSA) isoform p2PSA in combination with total PSA and free PSA improves diagnostic accuracy in prostate cancer detection. Eur Urol 57(6):921–927
55. Lazzeri M, Haese A, de la Taille A, Palou Redorta J, McNicholas T, Lughezzani G et al (2013) Serum isoform [−2]proPSA derivatives signifi cantly improve prediction of prostate cancer at initial biopsy in a total PSA range of 2–10 ng/ml: a multicentric European study. Eur Urol 63(6):986–994
56. Stephan C, Vincendeau S, Houlgatte A, Cammann H, Jung K, Semjonow A (2013) Multicenter evaluation of [−2]proprostate-specifi c antigen and the prostate health index for detecting prostate cancer. Clin Chem 59(1):306–314
57. Benson MC, Whang IS, Pantuck A, Ring K, Kaplan SA, Olsson CA et al (1992) Prostate specifi c antigen density: a means of distinguishing benign prostatic hypertrophy and prostate cancer. J Urol 147(3 Pt 2):815–816
58. Benson MC, McMahon DJ, Cooner WH, Olsson CA (1993) An algorithm for prostate cancer detection in a patient population using prostate-specifi c antigen and prostate-specifi c antigen density. World J Urol 11(4):206–213
59. Loeb S, Han M, Roehl KA, Antenor JA, Catalona WJ (2005) Accuracy of prostate weight estimation by digital rectal examination versus transrectal ultrasonography. J Urol 173(1):63–65
60. Connolly D, Black A, Murray LJ, Napolitano G, Gavin A, Keane PF (2007) Methods of calculating prostate-specifi c antigen velocity. Eur Urol 52(4):1044–1050
61. Carter HB, Pearson JD, Metter EJ, Brant LJ, Chan DW, Andres R et al (1992) Longitudinal evaluation of prostate-specifi c antigen levels in men with and without prostate disease. JAMA 267(16): 2215–2220
62. Carter HB, Ferrucci L, Kettermann A, Landis P, Wright EJ, Epstein JI et al (2006) Detection of lifethreatening prostate cancer with prostate-specifi c antigen velocity during a window of curability. J Natl Cancer Inst 98(21):1521–1527
63. Vickers AJ, Wolters T, Savage CJ, Cronin AM, O’Brien MF, Pettersson K et al (2009) Prostatespecifi c antigen velocity for early detection of prostate cancer: result from a large, representative, population-based cohort. Eur Urol 56(5):753–760
64. Wolters T, Roobol MJ, Bangma CH, Schroder FH (2009) Is prostate-specifi c antigen velocity selective for clinically signifi cant prostate cancer in screening? European randomized study of screening for prostate cancer (Rotterdam). Eur Urol 55(2):385–392
65. Thompson IM, Ankerst DP, Chi C, Goodman PJ, Tangen CM, Lucia MS et al (2006) Assessing prostate cancer risk: results from the prostate cancer prevention trial. J Natl Cancer Inst 98(8):529–534
66. Orsted DD, Bojesen SE, Kamstrup PR, Nordestgaard BG (2013) Long-term prostate-specifi c antigen velocity in improved classifi cation of prostate cancer risk and mortality. Eur Urol 64(3):384–393
67. Vickers AJ, Savage C, O’Brien MF, Lilja H (2009) Systematic review of pretreatment prostate-specifi c antigen velocity and doubling time as predictors for prostate cancer. J Clin Oncol 27(3):398–403
68. Vickers AJ, Till C, Tangen CM, Lilja H, Thompson IM (2011) An empirical evaluation of guidelines on prostate-specifi c antigen velocity in prostate cancer detection. J Natl Cancer Inst 103(6):462–469
69. D’Amico AV, Chen MH, Roehl KA, Catalona WJ (2004) Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. N Engl J Med 351(2):125–135
70. D’Amico AV, Renshaw AA, Sussman B, Chen MH (2005) Pretreatment PSA velocity and risk of death from prostate cancer following external beam radiation therapy. JAMA 294(4):440–447
71. Guideline Pc. Available from: http://www.uroweb.org/guidelines/online-guidelines/
72. Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC (1999) Natural history of progression after PSA elevation following radical prostatectomy. JAMA 281(17):1591–1597
73. Freedland SJ, Humphreys EB, Mangold LA, Eisenberger M, Dorey FJ, Walsh PC et al (2005) Risk of prostate cancer-specifi c mortality following biochemical recurrence after radical prostatectomy. JAMA 294(4):433–439
74. Freedland SJ, Humphreys EB, Mangold LA, Eisenberger M, Dorey FJ, Walsh PC et al (2007) Death in patients with recurrent prostate cancer after radical prostatectomy: prostate-specifi c antigen doubling time subgroups and their associated contributions to all-cause mortality. J Clin Oncol 25(13):1765–1771
75. Bul M, Zhu X, Valdagni R, Pickles T, Kakehi Y, Rannikko A et al (2013) Active surveillance for lowrisk prostate cancer worldwide: the PRIAS study. Eur Urol 63(4):597–603
76. Bussemakers MJ, van Bokhoven A, Verhaegh GW, Smit FP, Karthaus HF, Schalken JA et al (1999) DD3: a new prostate-specifi c gene, highly overexpressed in prostate cancer. Cancer Res 59(23): 5975–5979
77. Hessels D, Klein Gunnewiek JM, van Oort I, Karthaus HF, van Leenders GJ, van Balken B et al (2003) DD3(PCA3)-based molecular urine analysis for the diagnosis of prostate cancer. Eur Urol 44(1):8–15, discussion −6
78. Groskopf J, Aubin SM, Deras IL, Blase A, Bodrug S, Clark C et al (2006) APTIMA PCA3 molecular urine test: development of a method to aid in the diagnosis of prostate cancer. Clin Chem 52(6):1089–1095
79. Deras IL, Aubin SM, Blase A, Day JR, Koo S, Partin AW et al (2008) PCA3: a molecular urine assay for predicting prostate biopsy outcome. J Urol 179(4):1587–1592
80. Marks LS, Fradet Y, Deras IL, Blase A, Mathis J, Aubin SM et al (2007) PCA3 molecular urine assay for prostate cancer in men undergoing repeat biopsy. Urology 69(3):532–535
81. Haese A, de la Taille A, van Poppel H, Marberger M, Stenzl A, Mulders PF et al (2008) Clinical utility of the PCA3 urine assay in European men scheduled for repeat biopsy. Eur Urol 54(5):1081–1088
82. Auprich M, Haese A, Walz J, Pummer K, de la Taille A, Graefen M et al (2010) External validation of urinary PCA3-based nomograms to individually predict prostate biopsy outcome. Eur Urol 58(5):727–732
83. Roobol MJ, Schroder FH, van Leeuwen P, Wolters T, van den Bergh RC, van Leenders GJ et al (2010) Performance of the prostate cancer antigen 3 (PCA3) gene and prostate-specifi c antigen in prescreened men: exploring the value of PCA3 for a fi rst-line diagnostic test. Eur Urol 58(4):475–481
84. Bradley LA, Palomaki GE, Gutman S, Samson D, Aronson N (2013) Comparative effectiveness review: prostate cancer antigen 3 testing for the diagnosis and management of prostate cancer. J Urol 190(2):389–398
85. Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, Sun XW et al (2005) Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 310(5748):644–648
86. Laxman B, Tomlins SA, Mehra R, Morris DS, Wang L, Helgeson BE et al (2006) Noninvasive detection of TMPRSS2:ERG fusion transcripts in the urine of men with prostate cancer. Neoplasia 8(10):885–888
87. Laxman B, Morris DS, Yu J, Siddiqui J, Cao J, Mehra R et al (2008) A fi rst-generation multiplex biomarker analysis of urine for the early detection of prostate cancer. Cancer Res 68(3):645–649
88. Hessels D, Smit FP, Verhaegh GW, Witjes JA, Cornel EB, Schalken JA (2007) Detection of TMPRSS2-ERG fusion transcripts and prostate cancer antigen 3 in urinary sediments may improve diagnosis of prostate cancer. Clin Cancer Res 13(17):5103–5108
89. Tomlins SA, Aubin SM, Siddiqui J, Lonigro RJ, Sefton-Miller L, Miick S et al (2011) Urine TMPRSS2:ERG fusion transcript stratifi es prostate cancer risk in men with elevated serum PSA. Sci Transl Med 3(94):94ra72
90. Kuriyama M, Wang MC, Papsidero LD, Killian CS, Shimano T, Valenzuela L et al (1980) Quantitation of prostate-specifi c antigen in serum by a sensitive enzyme immunoassay. Cancer Res 40(12):4658–4662
91. Cookson MS, Aus G, Burnett AL, Canby-Hagino ED, D’Amico AV, Dmochowski RR et al (2007) Variation in the defi nition of biochemical recurrence in patients treated for localized prostate cancer: the American Urological Association Prostate Guidelines for Localized Prostate Cancer Update Panel report and recommendations for a standard in the reporting of surgical outcomes. J Urol 177(2):540–545
92. Roach M 3rd, Hanks G, Thames H Jr, Schellhammer P, Shipley WU, Sokol GH et al (2006) Defi ning biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO phoenix consensus conference. Int J Radiat Oncol Biol Phys 65(4):965–974
93. Antenor JA, Roehl KA, Eggener SE, Kundu SD, Han M, Catalona WJ (2005) Preoperative PSA and progression-free survival after radical prostatectomy for stage T1c disease. Urology 66(1):156–160
94. Vickers AJ, Cronin AM, Bjork T, Manjer J, Nilsson PM, Dahlin A et al (2010) Prostate specifi c antigen concentration at age 60 and death or metastasis from prostate cancer: case-control study. BMJ 341:c4521
95. Loeb S, Carter HB, Catalona WJ, Moul JW, Schroder FH (2012) Baseline prostate-specifi c antigen testing at a young age. Eur Urol 61(1):1–7
96. Zhu X, Albertsen PC, Andriole GL, Roobol MJ, Schroder FH, Vickers AJ (2012) Risk-based prostate cancer screening. Eur Urol 61(4):652–661
97. Lilja H, Cronin AM, Dahlin A, Manjer J, Nilsson PM, Eastham JA et al (2011) Prediction of signifi - cant prostate cancer diagnosed 20 to 30 years later with a single measure of prostate-specifi c antigen at or before age 50. Cancer 117(6):1210–1219
98. Vickers AJ, Ulmert D, Sjoberg DD, Bennette CJ, Bjork T, Gerdtsson A et al (2013) Strategy for detection of prostate cancer based on relation between prostate specifi c antigen at age 40–55 and long term risk of metastasis: case-control study. BMJ 346:f2023
99. Available from: http://www.prostaatwijzer.nl/medical-risk-calculators
100. Catalona WJ, Richie JP, Ahmann FR, Hudson MA, Scardino PT, Flanigan RC et al (1994) Comparison of digital rectal examination and serum prostate specifi c antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men. J Urol 151(5):1283–1290
101. Catalona WJ, Smith DS, Ratliff TL, Dodds KM, Coplen DE, Yuan JJ et al (1991) Measurement of prostate-specifi c antigen in serum as a screening test for prostate cancer. N Engl J Med 324(17):1156–1161
102. Catalona WJ, Smith DS, Ratliff TL, Basler JW (1993) Detection of organ-confi ned prostate cancer is increased through prostate-specifi c antigen-based screening. JAMA 270(8):948–954
103. Andriole GL, Crawford ED, Grubb RL 3rd, Buys SS, Chia D, Church TR et al (2012) Prostate cancer screening in the randomized prostate, lung, colorectal, and ovarian cancer screening trial: mortality results after 13 years of follow-up. J Natl Cancer Inst 104(2):125–132
104. Schroder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V et al (2012) Prostate-cancer mortality at 11 years of follow-up. N Engl J Med 366(11):981–990
105. Hugosson J, Carlsson S, Aus G, Bergdahl S, Khatami A, Lodding P et al (2010) Mortality results from the Goteborg randomised population-based prostatecancer screening trial. Lancet Oncol 11(8):725–732
106. Labrie F, Candas B, Cusan L, Gomez JL, Belanger A, Brousseau G et al (2004) Screening decreases prostate cancer mortality: 11-year follow-up of the 1988 Quebec prospective randomized controlled trial. Prostate 59(3):311–318
107. Kjellman A, Akre O, Norming U, Tornblom M, Gustafsson O (2009) 15-year followup of a population based prostate cancer screening study. J Urol 181(4):1615–1621, discussion 21
108. Sandblom G, Varenhorst E, Rosell J, Lofman O, Carlsson P (2011) Randomised prostate cancer screening trial: 20 year follow-up. BMJ 342:d1539
109. Jemal A, Ward E, Wu X, Martin HJ, McLaughlin CC, Thun MJ (2005) Geographic patterns of prostate cancer mortality and variations in access to medical care in the United States. Cancer Epidemiol Biomarkers Prev 14(3):590–595
110. Moyer VA, Force USPST (2012) Screening for prostate cancer: U.S. Preventive services task force recommendation statement. Ann Intern Med 157(2): 120–134
111. Chou R, Croswell JM, Dana T, Bougatsos C, Blazina I, Fu R et al (2011) Screening for prostate cancer: a review of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 155(11):762–771
112. Carlsson S, Vickers AJ, Roobol M, Eastham J, Scardino P, Lilja H et al (2012) Prostate cancer screening: facts, statistics, and interpretation in response to the US Preventive Services Task Force review. J Clin Oncol 30(21):2581–2584
113. Ilic D, Neuberger MM, Djulbegovic M, Dahm P (2013) Screening for prostate cancer. Cochrane Database Syst Rev 1:CD004720
114. Djulbegovic M, Beyth RJ, Neuberger MM, Stoffs TL, Vieweg J, Djulbegovic B et al (2010) Screening for prostate cancer: systematic review and metaanalysis of randomised controlled trials. BMJ 341:c4543
115. Roobol MJ, Carlsson S, Hugosson J (2011) Metaanalysis fi nds screening for prostate cancer with PSA does not reduce prostate cancer-related or allcause mortality but results likely due to heterogeneity – the two highest quality studies identifi ed do fi nd prostate cancer-related mortality reductions. Evid Based Med 16(1):20–21
116. Schroder F, Kattan MW (2008) The comparability of models for predicting the risk of a positive prostate biopsy with prostate-specifi c antigen alone: a systematic review. Eur Urol 54(2):274–290
117. van den Bergh RC, Roobol MJ, Wolters T, van Leeuwen PJ, Schroder FH (2008) The prostate cancer prevention trial and European randomized study of screening for prostate cancer risk calculators indicating a positive prostate biopsy: a comparison. BJU Int 102(9):1068–1073
118. Cavadas V, Osorio L, Sabell F, Teves F, Branco F, Silva-Ramos M (2010) Prostate cancer prevention trial and European randomized study of screening for prostate cancer risk calculators: a performance comparison in a contemporary screened cohort. Eur Urol 58(4):551–558
119. Oliveira M, Marques V, Carvalho AP, Santos A (2011) Head-to-head comparison of two online nomograms for prostate biopsy outcome prediction. BJU Int 107(11):1780–1783
120. Barentsz JO, Richenberg J, Clements R, Choyke P, Verma S, Villeirs G et al (2012) ESUR prostate MR guidelines 2012. Eur Radiol [Practice Guideline] 22(4):746–757
121. Park BK, Lee HM, Kim CK, Choi HY, Park JW (2008) Lesion localization in patients with a previous negative transrectal ultrasound biopsy and persistently elevated prostate specifi c antigen level using diffusion-weighted imaging at three Tesla before rebiopsy. Invest Radiol [Clinical Trial] 43(11):789–793
122. Sciarra A, Panebianco V, Ciccariello M, Salciccia S, Cattarino S, Lisi D et al (2010) Value of magnetic resonance spectroscopy imaging and dynamic contrast- enhanced imaging for detecting prostate cancer foci in men with prior negative biopsy. Clin Cancer Res [Clinical Trial Randomized Controlled Trial] 16(6):1875–1883
123. Iwazawa J, Mitani T, Sassa S, Ohue S (2011) Prostate cancer detection with MRI: is dynamic contrastenhanced imaging necessary in addition to diffusionweighted imaging? Diagn Interv Radiol [Comparative Study] 17(3):243–248
124. Tamada T, Sone T, Higashi H, Jo Y, Yamamoto A, Kanki A et al (2011) Prostate cancer detection in patients with total serum prostate-specifi c antigen levels of 4–10 ng/mL: diagnostic effi cacy of diffusion- weighted imaging, dynamic contrastenhanced MRI, and T2-weighted imaging. AJR Am J Roentgenol [Research Support, Non-US Gov’t] 197(3):664–670
125. Kitajima K, Kaji Y, Fukabori Y, Yoshida K, Suganuma N, Sugimura K (2010) Prostate cancer detection with 3 T MRI: comparison of diffusionweighted imaging and dynamic contrast-enhancedMRI in combination with T2-weighted imaging. J Magn Reson Imaging 31(3):625–631
126. Tanimoto A, Nakashima J, Kohno H, Shinmoto H, Kuribayashi S (2007) Prostate cancer screening: the clinical value of diffusion-weighted imaging and dynamic MR imaging in combination with T2-weighted imaging. J Magn Reson Imaging 25(1):146–152
127. Dickinson L, Ahmed HU, Allen C, Barentsz JO, Carey B, Futterer JJ et al (2013) Scoring systems used for the interpretation and reporting of multiparametric MRI for prostate cancer detection, localization, and characterization: could standardization lead to improved utilization of imaging within the diagnostic pathway? J Magn Reson Imaging 37(1):48–58
128. Moore CM, Kasivisvanathan V, Eggener S, Emberton M, Futterer JJ, Gill IS et al (2013) Standards of reporting for MRI-targeted biopsy studies (START) of the prostate: recommendations from an international working group. Eur Urol 64(4):544–552
129. Moore CM, Robertson NL, Arsanious N, Middleton T, Villers A, Klotz L et al (2013) Image-guided prostate biopsy using magnetic resonance imagingderived targets: a systematic review. Eur Urol 63(1):125–140
130. Kattan MW, Eastham JA, Wheeler TM, Maru N, Scardino PT, Erbersdobler A et al (2003) Counseling men with prostate cancer: a nomogram for predicting the presence of small, moderately differentiated, confi ned tumors. J Urol 170(5):1792–1797
131. Roemeling S, Roobol MJ, Kattan MW, van der Kwast TH, Steyerberg EW, Schroder FH (2007) Nomogram use for the prediction of indolent prostate cancer: impact on screen-detected populations. Cancer [Randomized Controlled Trial Research Support, Non-US Gov’t] 110(10):2218–2221
132. Shukla-Dave A, Hricak H, Akin O, Yu C, Zakian KL, Udo K et al (2012) Preoperative nomograms incorporating magnetic resonance imaging and spectroscopy for prediction of insignifi cant prostate cancer. BJU Int [Research Support, NIH, Extramural Validation Studies] 109(9):1315–1322